The occasion was intricately tied to a larger celebration—the 120th anniversary of Korea University—marking a century-plus of academic excellence and innovation. Unlike the previous year’s focus on medical informatics, this session pivoted towards the complex discipline of neuroscience, underscoring its critical role in advancing precision medicine. The forum aimed to carve a clear roadmap for future joint research endeavors, expanding the scientific horizons for both universities while reinforcing their commitment to nurturing leading physician-scientists.

Representatives from Yale University included notable figures such as Nancy J. Brown, Yale’s Dean of Medicine, whose administrative acumen shapes one of the world’s foremost medical schools. The delegation also featured Deputy Dean for Research Anthony Koleske, and Stephen M. Strittmatter, director of the prestigious Kavli Institute for Neuroscience. Their presence was complemented by clinical leaders like Emily J. Gilmore, head of Neurocritical Care and Emergency Neurology, along with expert neuroscientists Nenad Sestan and Janghoo Lim, who have pioneered advancements in genomics and genetics. Korea University was represented by its President Kim Dong-Won and a cadre of eminent faculty members specializing in physiology, neurology, neuroscience, and anatomy, collectively personifying the institution’s scientific vigor.

Structurally, the forum unfolded across three dynamic sessions, each methodically designed to traverse a comprehensive spectrum of contemporary neuroscience themes. The symposium commenced with opening remarks by Professor Park Hyun-mi, setting an academic tone that was warmly reinforced by congratulatory speeches from Presidents Kim Dong-Won and Yoon Eul-Sik, followed by Dean Brown’s keynote address. This inaugural session critically emphasized the transformation of medical education into an inquiry-driven process, where students cultivate the skills to interrogate and explore rather than passively receive knowledge. Dean Brown advocated for robust clinical and research training programs necessary for nurturing the next generation of physician-scientists, a foundational approach vital to driving clinical innovations.

The second session delved deeply into the clinical neuroscience terrain, featuring presentations from both Korean and Yale researchers. Key topics included neurodegenerative diseases and epilepsy, critical neurological disorders that demand sophisticated diagnostic and therapeutic approaches. Professors Kang Sung-Hoon and Roh Ji-hoon, alongside Deputy Directors and clinicians like Stephen M. Strittmatter and Emily J. Gilmore, showcased cutting-edge research and clinical trials addressing disease pathology and therapeutic stratagems. Their collective insights illuminated progress in understanding the molecular and cellular underpinnings of these brain disorders, employing innovative methodologies such as neuroimaging, genetic profiling, and electrophysiological monitoring.

Transitioning into the third session, basic neuroscience research was foregrounded, focusing on synaptic circuitry, molecular targets implicated in brain disease, and the application of brain organoid models. Deputy Dean Anthony Koleske and Executive Director Nenad Sestan led discussions on how molecular biophysics and genome editing techniques are unraveling the complexities of neuronal connectivity and plasticity. The exploration of brain organoids — three-dimensional clusters of neural cells cultivated in vitro to mimic aspects of brain tissue — represents a transformative approach to studying neurodevelopmental processes and disease modeling. This session facilitated in-depth deliberation on how such foundational research informs clinical applications, creating synergies between bench science and bedside care.

Before the public forum, a working-level meeting solidified a strategic vision for ongoing collaboration, including an agreement to host this joint neuroscience forum annually. Preparations have already commenced for the 2028 event, aligning with Korea University’s forthcoming centennial milestone for its College of Medicine. Additionally, a key initiative involves dispatching a Yale University professor responsible for the Physician Scientist Training Program to Korea University, ensuring that insights and best practices regarding training systems for physician-scientists are effectively shared and adapted. This programmatic exchange reflects a deep commitment to cultivating medical researchers whose integrated expertise bridges laboratory and clinical realms.

Further enriching the forum were scientific short talks by Korean experts such as Professors Park Jin-Woo, Kim Chi-Kyung, Baek Seol-Hee, and Kim Eun-Ha, who presented recent advancements in neuroscience research underpinning potential collaborative endeavors with Yale’s School of Medicine. These presentations covered emerging topics within neurophysiology, neurogenetics, and innovative clinical methodologies, illustrating a fertile ground for cross-institutional projects and the translation of discoveries into therapeutic innovations.

Throughout the event, Dean Pyun Sung-Bom of Korea University’s College of Medicine emphasized the critical duality of neuroscience in linking fundamental biological discovery with clinical practice. He highlighted neuroscience as a cornerstone discipline for future precision medicine initiatives, underscoring the potential of the joint forum to catalyze an expanded global network of research and educational exchange. This nexus between basic science and clinical application is poised to accelerate breakthroughs in diagnosing, understanding, and treating complex neurological conditions.

The interdisciplinary nature of the forum reflected a convergence of diverse scientific fields, including molecular neuroscience, cellular neuroscience, and clinical neuroscience. By integrating expertise from these domains, the forum fostered a holistic approach to addressing intricate challenges such as synaptic dysfunction, neurodegeneration, and neural circuit remodeling. Cutting-edge technologies, including genome editing and organoid cultures, were central to these discussions, illustrating how modern tools are revolutionizing neuroscience research and opening new frontiers in biomedical science.

Importantly, the forum also emphasized the cultivation of the next generation of neuroscientists with cross-disciplinary skill sets. The collaboration between Korea University and Yale University seeks to establish robust educational frameworks that foster scientific curiosity, critical thinking, and translational research capabilities. This approach aligns with the emerging paradigm in medical education that prioritizes integrative and experiential learning, preparing trainees to lead future innovations at the intersection of neuroscience research and clinical care.

Reflecting on the event’s outcomes, the joint forum signaled a pivotal commitment to sustained global collaboration, leveraging complementary strengths of each institution. By formalizing annual meetings and targeted exchanges in education and research training, Korea University and Yale University are laying the foundation for a vibrant international neuroscience community. This partnership models how academic alliances can harness collective expertise to confront pressing neurological disorders with unprecedented depth and nuance.

The discussions at the forum underscored neuroscience’s transformative potential in shaping personalized therapeutic strategies, particularly through precision medicine frameworks that tailor interventions based on molecular and genetic profiles. As advances continue in imaging, molecular biology, and neuroinformatics, the synergy between basic neuroscience and clinical practice cultivated by this forum will be instrumental in steering future breakthroughs from conceptual discovery to clinical reality.

In summary, the Korea University-Yale University Joint Forum on Basic and Clinical Neuroscience was a landmark event that showcased the power of international collaboration and interdisciplinary research. By bridging fundamental and translational neuroscience, fostering innovative education programs, and committing to sustained partnership, the forum exemplifies a forward-looking model essential for navigating the complexities of brain science in the 21st century.

Subject of Research: Neuroscience, including clinical and basic research on neurodegenerative diseases, epilepsy, synaptic circuits, brain molecules, and brain organoids.

Article Title: Korea University and Yale University Forge a Groundbreaking Partnership in Basic and Clinical Neuroscience

News Publication Date: October 28, 2024

Web References:
https://mediasvc.eurekalert.org/Api/v1/Multimedia/840a9b26-8419-48e3-8288-5242800f8fc6/Rendition/low-res/Content/Public

Image Credits: KU Medicine

Keywords: Neuroscience, Clinical neuroscience, Cellular neuroscience, Molecular neuroscience

Dr. Charney’s research contributions have been pivotal in advancing our understanding of complex psychiatric disorders. As a neurobiologist specializing in the molecular bases of anxiety, fear, depression, and resilience, his work has yielded groundbreaking insights that have directly informed the development of novel therapeutic interventions. Notably, Dr. Charney was recognized as one of the 2025 TIME 100 Health Most Influential People in Health, a testament to his innovative approach and success in creating breakthrough treatments for depression. His research into the neurochemical pathways involved in mood regulation has helped usher in new pharmacological agents that offer hope to millions suffering from mental health conditions.

Under Dr. Charney’s visionary leadership, the Icahn School of Medicine embarked on a profound journey of expansion and scientific discovery. He actively cultivated a multidisciplinary environment by recruiting top-tier faculty across various fields such as biomedical sciences, computational biology, and information technology. This convergence of disciplines fostered an ecosystem of scientific risk-taking and resource sharing that challenged conventional boundaries within academic medicine. The school’s commitment to interdisciplinary collaboration led to the establishment of over two dozen research institutes dedicated to cutting-edge investigations in cancer, cardiovascular diseases, gastrointestinal disorders, and psychiatric illnesses, highlighting the school’s broad impact in multiple medical domains.

A defining hallmark of Dr. Charney’s tenure was the dramatic increase in funding from the National Institutes of Health (NIH), which soared to an unprecedented $500 million annually by 2024. This influx situates the Icahn School of Medicine at Mount Sinai as the 11th highest recipient of NIH funding among all U.S. medical schools and places it in the 99th percentile for research funding among private institutions. This financial support has empowered the school to advance its research infrastructure, recruit leading scientists, and train the next generation of medical innovators. Moreover, the expansion of the graduate medical education program under Dr. Charney’s leadership created the largest residency and clinical fellowship cohort in the nation, now exceeding 2,600 trainees.

Dr. Charney also forged strategic partnerships with technological and academic powerhouses such as the Hasso Plattner Institute, Rensselaer Polytechnic Institute, and the State University of New York at Stony Brook. These collaborations have been instrumental in developing digital health tools that advance precision medicine—a rapidly emerging field that leverages data analytics, machine learning, and personalized biological insights to optimize patient care. One historic advancement co-invented by Dr. Charney is ketamine, an FDA-approved rapid-acting antidepressant marketed as SPRAVATO™. Ketamine’s novel mechanism of action has revolutionized treatment paradigms for resistant depression, offering patients fast and effective relief where traditional antidepressants often fail.

In addition to pharmacological innovations, Dr. Charney is a pioneer in the digital therapeutics space, having co-developed Rejoyn, the first FDA-approved prescription digital therapeutic for major depressive disorder (MDD). This technology employs computer-guided behavioral therapy and data-driven patient engagement strategies that complement traditional medical treatments. Such digital interventions epitomize the future of mental health care, blending psychological science with software engineering to expand accessibility and efficacy. Dr. Charney’s dual achievement in both chemical and digital therapeutics exemplifies his comprehensive and forward-thinking approach to mental health research and treatment.

His scientific excellence has been recognized through numerous prestigious awards, cementing his status as a leader in psychiatric research. Dr. Charney was inducted into the National Academy of Medicine in 2000, a distinction reserved for individuals who have made profound contributions to medical science. His accolades include the Colvin Prize for Outstanding Achievement in Mood Disorder Research awarded in 2019 and the Rhoda & Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine in 2023. These honors highlight his sustained commitment to understanding and addressing the biological underpinnings of mental illness.

The Mount Sinai Health System leadership has lauded Dr. Charney’s transformational impact on the school and health system. Brendan G. Carr, MD, and Kenneth L. Davis, MD, praised his ability to assemble a world-class team and secure the necessary resources that will sustain the school’s trajectory of excellence. They emphasized his unique leadership qualities that blend innovative thinking with steadfast dedication. Similarly, Kenneth L. Davis reflected on Dr. Charney’s “outside-the-box” leadership style, which defied traditional constraints and forged a culture strong enough to elevate the Icahn School of Medicine into a premier institution for biomedical education and research.

Echoing this sentiment, Richard A. Friedman and James S. Tisch, Co-Chairs of the Mount Sinai Health System Boards of Trustees, referred to Dr. Charney as a visionary transformative leader who successfully implanted an entrepreneurial spirit within the school. By fostering an environment conducive to innovation and risk-taking, Dr. Charney created a dynamic academic culture that continues to push the boundaries of biomedical research and patient care. His strategic direction is seen as a cornerstone of the institution’s success and future potential.

In the wake of this leadership transition, Eric J. Nestler, MD, PhD, has been appointed as Interim Dean of the Icahn School of Medicine. Dr. Nestler is a distinguished molecular neuroscientist known for his work on the mechanisms underlying addiction and depression. He has served as Dean for Academic Affairs since 2016 and as Chief Scientific Officer of the Mount Sinai Health System, with a prolific publication record of over 750 papers and five books. His election to the National Academy of Sciences—the highest honor for original scientific research—underscores his stature in the biomedical community and promises continuity in the school’s scientific mission.

Mount Sinai Health System itself stands as a pillar of comprehensive care and biomedical innovation in the New York metropolitan area. Employing 48,000 staff across seven hospitals, over 400 outpatient practices, and more than 600 research and clinical laboratories, it is among the largest academic medical systems in the region. The Health System’s integrated model combines cutting-edge scientific research, education, and clinical care to address complex health challenges using novel technologies including artificial intelligence and informatics. Its hospitals routinely receive accolades from Newsweek and U.S. News & World Report, reflecting their excellence in healthcare delivery.

The Icahn School of Medicine’s ever-expanding research footprint and educational programs have played an essential role within this ecosystem. Taking advantage of state-of-the-art facilities and a comprehensive network of healthcare providers, faculty and students are uniquely positioned to translate scientific discoveries into tangible health improvements. The synergy between research and clinical enterprises fuels innovations that continue to broaden treatment options for a wide spectrum of diseases, from cancer and heart disease to psychiatric and gastrointestinal disorders.

Looking ahead, the Icahn School of Medicine at Mount Sinai is poised to build on the foundation laid by Dr. Charney’s leadership. The school’s emphasis on cross-disciplinary collaboration, augmented by strategic partnerships and cutting-edge digital health innovations, positions it as a global leader ready to tackle the evolving challenges of medicine. As Dr. Nestler steps into his interim role, the institution’s vibrant culture of research excellence and education stands insured, ensuring that the next generation of physicians and scientists will carry the torch forward.

Subject of Research: Neurobiology of mood disorders, mechanisms of depression and anxiety, development of novel pharmacological and digital therapeutics.

Article Title: Not explicitly provided in the source content.

News Publication Date: May 13, 2025

Web References:
https://time.com/collections/time100-health-2025/7279649/dennis-charney/

Keywords: Health and medicine, neurobiology, depression, anxiety, resilience, ketamine, SPRAVATO™, digital therapeutics, Rejoyn, biomedical innovation, academic medicine, precision medicine.